首页> 外文期刊>Clinical & developmental immunology. >Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
【24h】

Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis

机译:晚期胰腺癌特异性免疫治疗的临床结果:系统评价和荟萃分析

获取原文
获取外文期刊封面目录资料

摘要

Specific immunotherapies, including vaccines with autologous tumor cells and tumor antigen-specific monoclonal antibodies, are important treatments for PC patients. To evaluate the clinical outcomes of PC-specific immunotherapy, we performed a systematic review and meta-analysis of the relevant published clinical trials. The effects of specific immunotherapy were compared with those of nonspecific immunotherapy and the meta-analysis was executed with results regarding the overall survival (OS), immune responses data, and serum cancer markers data. The pooled analysis was performed by using the random-effects model. We found that significantly improved OS was noted for PC patients utilizing specific immunotherapy and an improved immune response was also observed. In conclusion, specific immunotherapy was superior in prolonging the survival time and enhancing immunological responses in PC patients.
机译:特异性免疫疗法,包括带有自体肿瘤细胞的疫苗和肿瘤抗原特异性单克隆抗体,是PC患者的重要治疗方法。为了评估PC特异性免疫疗法的临床结果,我们对相关已发表的临床试验进行了系统的综述和荟萃分析。将特异性免疫疗法的效果与非特异性免疫疗法的效果进行比较,并进行荟萃分析,得出有关总生存期(OS),免疫应答数据和血清癌标志物数据的结果。通过使用随机效应模型进行汇总分析。我们发现使用特异性免疫疗法的PC患者OS明显改善,并且免疫反应也得到改善。总之,特异性免疫疗法在延长PC患者的生存时间和增强免疫应答方面具有优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号